Project Grant K08CA308865
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $273K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $752,808 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate clonal hematopoiesis as a mechanism of therapeutic resistance in anaplastic thyroid cancer. The research examines how clonal hematopoiesis—the age-related expansion of mutant hematopoietic stem and progenitor cells—drives resistance to BRAF-MEK inhibitor therapy in anaplastic thyroid cancer patients. The project...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $645,233 on August 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate hormone regulation of fallopian tube inflammation and cancer initiation via a stromal niche. The project examines how estrogen signaling in fallopian tube stromal cells drives chronic inflammation and promotes ovarian cancer initiation. The research builds on preliminary findings identifying estrogen receptor-positive...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $1.73 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2025 through August 31, 2028. The research project focuses on investigating the role of specific long non-coding RNAs (lncRNAs) in combined therapeutic approaches to modulate the thrombospondin-1 (TSP1)-dependent immune microenvironment...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $191,484 on August 13, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and validate computational methods for early cancer detection using mutational signature analysis. The project expands mutational signature methodology to identify DNA repair deficiencies in high-risk patients with genetic predisposition to cancer. Aim 1 broadens the predictive framework to detect multiple types of DNA...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded Mayo Clinic $676,067 on March 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate artificial intelligence and natural language processing systems for identifying and characterizing incidental thyroid nodules in imaging reports. The project addresses thyroid cancer overdiagnosis driven by detection of small, asymptomatic papillary thyroid cancers that impose significant medical and financial burdens...
- The National Cancer Institute awarded Brigham & Women's Hospital $772,208 on April 10, 2026, under Cancer Treatment Research (CFDA 93.395) to conduct macrophage-directed strategies for BRCA-associated breast cancer treatment, with performance through March 31, 2031. The recipient is characterizing tumor microenvironment responses to combined PARP inhibition (olaparib) and anti-CSF-1R antibody (axatilimab) therapy in patients enrolled in the AXALAP clinical trial. Work includes analysis of...